Protective Effects ofJA845 against D-Galactose/AlCl-Induced Cognitive Decline, Oxidative Stress and Neuroinflammation.

Abstract

Recently, the efficacy of probiotics in treatment of neurodegenerative disorders has been reported in animal and clinical studies. Here, we assessed the effects ofJA845 in counteracting the symptoms of D-galactose (D-gal)/AlCl-induced Alzheimer's disease (AD) in a mice model through behavioral test, histological assessment and biochemical analysis. Ten weeks of pre-treatment withJA845 prevented cognitive decline, attenuated hippocampal lesion and protected neuronal integrity, which demonstrated the neuroprotective features ofJA845 in vivo. We also found that supplementation ofJA845 alleviated amyloid-beta deposits and hyperphosphorylated tau in hippocampus of D-gal/AlCl-induced AD model mice. Furthermore,JA845 administration attenuated oxidative stress and decreased serum concentration of inflammatory cytokines by regulating the Nrf2/HO-1 and MyD88/TRAF6/NF-κB pathway. Our results demonstrated for the first time thathas the potential to help prevent cognitive decline and might be a novel therapeutic approach for the treatment of neurodegenerative diseases.